The impacts of the novel SARS-CoV-2 outbreak on surgical oncology - A letter to the editor on “The socio-economic implications of the coronavirus and COVID-19 pandemic: A review”

Shubber, Nour; Sheppard, Jack; Alradhawi, Mohammad; Ali, Yousif

doi:10.1016/j.ijsu.2020.05.032

Cited by 10 publications

(6 citation statements)

References 3 publications

(3 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A global survey of 351 cancer centres, conducted in April/May 2020, reported that 88.2% of centres reduced their usual care, and the most common reason was due to precautionary measures [ 10 ]. However, centres in Canada and other countries are also reporting fewer referrals from general practitioners to oncology providers for diagnosis or treatment [ 8 , 34 , 35 ]. This may mean Ontario could see a reduction in treatment volumes and the need for the interim funding measures in the coming months may be reduced.…”

Section: Discussionmentioning

confidence: 99%

“…Accordingly, prescribers are challenged with balancing the risks and benefits of treating cancer patients who are also impacted, both directly and indirectly, by COVID-19. As countries try to contain the spread of COVID-19 and manage active COVID-19 infections, cancer patients may face treatment interruptions or delays in accessing standard diagnostic procedures and treatment modalities, including curative surgeries, radiation, and systemic therapies [ 8 , 9 , 10 , 11 , 12 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinician Perspectives of COVID-19-Related Cancer Drug Funding Measures in Ontario

et al. 2021

View full text Add to dashboard Cite

The COVID-19 pandemic has a significant impact on cancer patients and the delivery of cancer care. To allow clinicians to adapt treatment plans for patients, Ontario Health (Cancer Care Ontario) issued a series of interim funding measures for the province’s New Drug Funding Program (NDFP), which covers the cost of most hospital-delivered cancer drugs. To assess the utility of the measures and the need for their continuation, we conducted an online survey of Ontario oncology clinicians. The survey was open 3–25 September 2020 and generated 105 responses. Between April and June 2020, 46% of respondents changed treatment plans for more than 25% of their cancer patients due to the pandemic. Clinicians report broad use of interim funding measures. The most frequently reported strategies used were treatment breaks for stable patients (62%), extending dosing intervals (59%), and deferring routine imaging (56%). Most clinicians anticipate continuing to use these interim funding measures in the coming months. The survey showed that adapting cancer drug funding policies has supported clinical care in Ontario during the pandemic.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Clinician Perspectives of COVID-19-Related Cancer Drug Funding Measures in Ontario

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Designated COVID-19-restricted centers might potentially be better for performing cancer surgery, and periodic testing of involved healthcare staff is also warranted to mitigate disease transmission between hospital staff and patients. The need for designated COVID-19-free hospitals to offer continued cancer care was recommended by Restivo et al [ 14 ] after their initial observation of the pandemic in Italy and has also been recommended by others [ 12 , 15 ]. These facilities must implement standardized, mandatory preoperative testing pathways before patient admission.…”

Section: Discussionmentioning

confidence: 99%

What Proportion of Patients with Bone and Soft Tissue Tumors Contracted Coronavirus-19 and Died From Surgical Procedures During the Initial Period of the COVID-19 Pandemic? Results From the Multicenter British Orthopaedic Oncology Society Observational Study

Rajasekaran

Ashford

Cosker

et al. 2020

Clin Orthop Relat Res

View full text Add to dashboard Cite

Background Delivering uninterrupted cancer treatment to patients with musculoskeletal tumors has been essential during the rapidly evolving coronavirus 2019 (COVID-19) pandemic, as delays in management can be detrimental. Currently, the risk of contracting COVID-19 in hospitals when admitted for surgery and the susceptibility due to adjuvant therapies and associated mortality due to COVID-19 is unknown, but knowledge of these potential risks would help treating clinicians provide appropriate cancer care. Questions/purposes (1) What is the risk of hospital-acquired COVID-19 in patients with musculoskeletal tumors admitted for surgery during the initial period of the pandemic? (2) What is the associated mortality in patients with musculoskeletal tumors who have contracted COVID-19? (3) Are patients with musculoskeletal tumors who have had neoadjuvant therapy (chemotherapy or radiation) preoperatively at an increased risk of contracting COVID-19? (4) Is a higher American Society of Anesthesiologists (ASA) grade in patients with musculoskeletal tumors associated with an increased risk of contracting COVID-19 when admitted to the hospital for surgery? Methods This retrospective, observational study analyzed patients with musculoskeletal tumors who underwent surgery in one of eight specialist centers in the United Kingdom, which included the five designated cancer centers in England, one specialist soft tissue sarcoma center, and two centers from Scotland between March 12, 2020 and May 20, 2020. A total of 347 patients were included, with a median (range) age of 53 years (10 to 94); 60% (207 of 347) were men, and the median ASA grade was II (I to IV). These patients had a median hospital stay of 8 days (0 to 53). Eighteen percent (61 of 347) of patients had received neoadjuvant therapy (8% [27] chemotherapy, 8% [28] radiation, 2% [ 6 ] chemotherapy and radiation) preoperatively. The decision to undergo surgery was made in adherence with United Kingdom National Health Service and national orthopaedic oncology guidelines, but specific data with regard to the number of patients within each category are not known. Fifty-nine percent (204 of 347) were negative in PCR testing done 48 hours before the surgical procedure; the remaining 41% (143 of 347) were treated before preoperative PCR testing was made mandatory, but these patients were asymptomatic. All patients were followed for 30 days postoperatively, and none were lost to follow-up during that period. The primary outcome of the study was contracting COVID-19 in the hospital after admission. The secondary outcome was associated mortality after contracting COVID-19 within 30 days of the surgical procedure. In addition, we assessed whether there is any association between ASA grade or neoadjuvant treatment and the chances of contracting COVID-19 in the hospital. Electronic patient record system and simple descriptive statistics were used to analyze b...

show abstract

“…32 Por su parte el NHS de Inglaterra reportó una disminución del 60% en las citas de quimioterapia para pacientes con cáncer en comparación con los niveles anteriores a COVID-19. 34 La revisión del estudio DATA-CAN que analizó los registros clínicos de más de 3 millones de adultos, demuestran caídas en las admisiones para quimioterapia similares (reducción del 45-66%). 17…”

Section: Terapia Sistémicaunclassified

Impacto de la pandemia por coronavirus (SARS-CoV-2) en el diagnóstico, tratamiento y seguimiento de los pacientes oncológicos

Miranda-Olivares

Lira-Correa

Bermúdez-Valenzuela

et al. 2021

Rev. chil. salud pública

View full text Add to dashboard Cite

El síndrome respiratorio agudo severo por coronavirus (SARS-CoV-2) ha generado una pandemia que ha requerido ajustes significativos en los sistemas de salud mundiales, tanto a nivel hospitalario como ambulatorio. Para patologías crónicas no transmisibles, como las oncológicas, esta pandemia ha tenido repercusiones importantes especialmente a nivel primario de atención. Se ha afectado el manejo oncológico integral, desde la detección precoz, el tratamiento, los exámenes de control y el seguimiento de los pacientes. Entre ellos destaca la disminución, a nivel mundial, del número de procedimientos diagnósticos digestivos, de imágenes, citológicos, quirúrgicos, de tratamiento sistémico, consultas e interconsultas oncológicas. Diversas organizaciones han recopilado cifras de ello y han proyectado cifras de como la disminución de diagnóstico oportuno o el retraso y/o interrupción del tratamiento repercutirán en un aumento de la morbimortalidad. Por ello, han elaborado guías de recomendaciones para minimizar el riesgo de contagio por coronavirus, para retomar a la brevedad el nivel de atención. Esta revisión ejemplifica el impacto de la pandemia de COVID-19 en el manejo habitual de los pacientes con patologías oncológicas, lo que permitirá dimensionar su efecto, así como delinear un plan multidisciplinario de recuperación y puesta al día en el manejo integral de los pacientes oncológicos.

show abstract

The impacts of the novel SARS-CoV-2 outbreak on surgical oncology - A letter to the editor on “The socio-economic implications of the coronavirus and COVID-19 pandemic: A review”

Cited by 10 publications

References 3 publications

Clinician Perspectives of COVID-19-Related Cancer Drug Funding Measures in Ontario

Clinician Perspectives of COVID-19-Related Cancer Drug Funding Measures in Ontario

What Proportion of Patients with Bone and Soft Tissue Tumors Contracted Coronavirus-19 and Died From Surgical Procedures During the Initial Period of the COVID-19 Pandemic? Results From the Multicenter British Orthopaedic Oncology Society Observational Study

Impacto de la pandemia por coronavirus (SARS-CoV-2) en el diagnóstico, tratamiento y seguimiento de los pacientes oncológicos

Contact Info

Product

Resources

About